Fimasartan clinical trials
Includes 2 studies of Fimasartan potassium trihydrate.
How each study uses fimasartan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the fimasartan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
50 studies that test it; most in 2009 (7)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 7 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 6 |
| 2013 | 3 |
| 2014 | 7 |
| 2015 | 6 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 42 · Other 8
Boryung Pharmaceutical Co., Ltd (40) · Seoul National University Hospital (2) · R-Pharm (1) · Asan Medical Center (1) · Stendhal Americas, S.A. (1) · Seoul National University Bundang Hospital (1) · Seung-Jung Park (1) · Centro Universitario de Ciencias de la Salud, Mexico (1)
Often tested with
Tested in the same studies.
Amlodipine (9) · Rosuvastatin (7) · Atorvastatin (6) · Hydrochlorothiazide (3) · Indapamide (2) · Ezetimibe (1) · Candesartan cilexetil (1) · Candesartan (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses fimasartan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 50
- Effect of Fimasartan on Extended RAS and Vascular Functions in Patients With Type 2 Diabetes and HypertensionRecruitingPhase 4Seoul National University Bundang HospitalNCT05173025Written as FimasartanHow we know
- A Study to Evaluate the Efficacy and Safety of BR1015 Combination TherapyCompletedPhase 3Boryung Pharmaceutical Co., LtdNCT05878561Written as Fimasartan + IndapamideHow we know
- A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary HypercholesterolemiaCompletedPhase 3Boryung Pharmaceutical Co., LtdNCT05930028Written as FimasartanHow we know
- A Clinical Trial to Evaluate Drug-drug Interactions and Safety Between "BR1015-1" and "BR1015-2" in Healthy VolunteersCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT05097794Written as BR1015-1How we know
- BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine CombinationCompletedPhase 3Boryung Pharmaceutical Co., LtdNCT03991442Written as Fimasartan/AmlodipineHow we know
- A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and DyslipidemiaCompletedPhase 3Boryung Pharmaceutical Co., LtdNCT03338426Written as Fimasartan 120mgHow we know
- Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and DyslipidemiaCompletedPhase 3Boryung Pharmaceutical Co., LtdNCT03156842Written as Fimasartan/Amlodipine, RosuvastatinHow we know
- Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial HypertensionCompletedPhase 3R-PharmNCT02248961Written as FimasartanHow we know
- A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male SubjectsCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT02704702Written as FimasartanHow we know
- Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)TerminatedPhase 4Seung-Jung ParkNCT01384747Written as FimasartanHow we know
- Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension PatientsCompletedPhase 3Boryung Pharmaceutical Co., LtdNCT00922480Written as FimasartanHow we know
- A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential HypertensionCompletedPhase 2Boryung Pharmaceutical Co., LtdNCT00922441Written as Fimasartan 60 mg groupHow we know
- A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Atorvastatin in Healthy Male Volunteers.CompletedPhase 1Boryung Pharmaceutical Co., LtdNCT02994745Written as Fimasartan, AtorvastatinHow we know
- A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Amlodipine in Healthy Male SubjectsCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT02920047Written as Fimasartan/AmlodipineHow we know
- Fimasartan Plus Amlodipine on Hemodynamic Parameters and Arterial Stiffness in Patients With HypertensionStatus unknownPhase 4Centro Universitario de Ciencias de la Salud, MexicoNCT03294070Written as Fimasartan plus amlodipine besylateHow we know
- Fimasartan Achieving SBP Target (FAST) StudyCompletedPhase 4Boryung Pharmaceutical Co., LtdNCT02495324Written as FimasartanHow we know
- Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic PatientsCompletedNot applicableSeoul National University HospitalNCT02312375Written as FimasartanHow we know
- A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and DyslipidemiaCompletedPhase 3Boryung Pharmaceutical Co., LtdNCT02166814Written as Fimasartan and RosuvastatinHow we know
- Comparison of Blood Pressure Lowering Effect Between Fimasartan and LosartanStatus unknownPhase 4Chuncheon Sacred Heart HospitalNCT02958631Written as FimasartanHow we know
- Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive PatientsCompletedPhase 4Boryung Pharmaceutical Co., LtdNCT01736488Written as FimasartanHow we know
See all 50 studies that test fimasartan →
As the comparator · 7 — what is tested is compared with fimasartan
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed ConditionsNot yet recruitingPhase 1Boryung Pharmaceutical Co., LtdNCT07421388Written as BR1015-1How we know
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting ConditionsNot yet recruitingPhase 1Boryung Pharmaceutical Co., LtdNCT07421375Written as BR1015-1How we know
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting ConditionsCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT06744127Written as BR1015-1How we know
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed ConditionsCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT06744062Written as BR1015-1How we know
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fasting Conditions in Healthy VolunteersCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT06008028Written as BR1015-1How we know
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy VolunteersCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT06008015Written as BR1015-1How we know
- Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K)CompletedPhase 2Boryung Pharmaceutical Co., LtdNCT00937651Written as Fimasartan (BR-A-657•K) 20 mgHow we know
Codes
What other systems call fimasartan · ClinicalTrials.gg INT005848
- MeSH (NLM) C558933fimasartanOne source NLM
- UNII (FDA) P58222188PFIMASARTANConfirmed FDA, NLM, Wikidata
- Wikidata Q8563179fimasartanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C81417FimasartanOne source FDA
- DrugBank DB09279One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C558933 | fimasartan | One source NLM |
| UNII (FDA) | P58222188P | FIMASARTAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q8563179 | fimasartan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C81417 | Fimasartan | One source FDA |
| DrugBank | DB09279 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.